SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
BlackRock Health Sciences Trust (BME) trades at a trailing P/E of 6.8. Trailing earnings yield is 14.77%. PEG 0.03 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (100/100, Pass) — P/E is below market average (6.8); PEG ≤ 1.0 — Peter Lynch undervalued (0.03); earnings yield beats bond yields (14.77%).
- PEG Ratio 0.03 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 14.77% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
Overall SharesGrow Score: 84/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — BME
Valuation Multiples
P/E (TTM)6.8
Forward P/EN/A
PEG Ratio0.03
Forward PEGN/A
P/B Ratio0.00
P/S Ratio14.40
EV/EBITDA0.0
Per Share Data
EPS (TTM)$5.92
Book Value / Share$0.00
Revenue / Share$2.78
FCF / Share$0.00
Yields & Fair Value
Earnings Yield14.77%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$1.45 |
$0.00 |
$0.00 |
- |
| 2020 |
$11.63 |
$0.00 |
$0.00 |
- |
| 2021 |
$-2.55 |
$0.00 |
$0.00 |
- |
| 2022 |
$-2.10 |
$-25.97M |
$-26.47M |
- |
| 2023 |
$1.44 |
$20.41M |
$20.02M |
98.1% |
| 2024 |
$1.68 |
$24.07M |
$23.45M |
97.4% |
| 2025 |
$5.92 |
$36.16M |
$76.97M |
212.9% |
